-
Front Oncol: Real-world assessment of the long-term efficacy of first-line pembrolizumab monotherapy in advanced NSCLC patients with PD-L1 ≥ 50%
Time of Update: 2022-04-23
The study included two cohorts of patients: the electronic medical record cohort (EHR cohort) and the manual review cohort (spotlight cohort), and assessed overall survival (OS) in the two cohorts, and real-world progression-free survival (rwPFS) in the spotlight cohort and real-world Tumor Response (rwTR) .
-
BMC Cancer: Real-world efficacy of lenvatinib combined with PD-1 inhibitors in advanced hepatocellular carcinoma
Time of Update: 2022-04-23
Mainly to evaluate the efficacy of lenvatinib combined with PD-1 inhibitor in the treatment of patients with advanced hepatocellular carcinoma, especially if the tumor occupies ≥50% of the liver volume (TO ≥50%) or Vp4 invasion .
-
The world's first first-line treatment of SCLC with positive results of PD-1 inhibitor data announced!
Time of Update: 2021-12-29
The ASTRUM-005 study is a randomized, double-blind, international multi-center, phase III clinical study that evaluated slulimumab and placebo combined with chemotherapy for the treatment of previously untreated extensive-stage small cell lung cancer (ES-SCLC) Patient effectiveness and safety .
-
The world's first subcutaneous PD-L1 envolimab is approved for marketing in China
Time of Update: 2021-12-05
Recently, according to the latest announcement by the National Medical Products Administration (NMPA) of China, Corning Jereh, Siddi Medicine, and Simcere Pharmaceuticals have reached a strategic cooperation with Class 1 biological drug Envolimab Injection (KN035) that has been qualified.
-
The world's first subcutaneous injection of PD-L1 drug is here!
Time of Update: 2021-12-05
As an innovative drug, Envolimab is in II Shortly after the release of the data of the first phase of the study, it was quickly included in the priority review and was approved recently, officially entering the field of advanced solid tumors in China’s MSI-H/dMMR, bringing new treatment options and survival hopes to patients, and also leading Chinese tumors Immunotherapy is moving further towards the era of precision treatment .
-
The world's first oral small molecule PD-(L)1 human test data disclosure
Time of Update: 2021-12-04
According to the previous public information of Betta Pharmaceuticals' application for Hong Kong stocks, BPI-371153 is an innovative, oral small molecule PD-L1 inhibitor that can achieve an anti-tumor immune response comparable to anti-PD-L1 antibodies in preclinical studies .
-
The world's first subcutaneous PD-L1 envolimab was approved for marketing in China
Time of Update: 2021-12-04
On November 25, the National Medical Products Administration approved the subcutaneous injection of PD-L1 antibody envolimab for MSI-H/dMMR advanced colorectal cancer, gastric cancer and other solid tumors that have failed standard treatment .
It is currently the world's first approved PD-(L)1 antibody for subcutaneous injection .
-
The world's first subcutaneous injection and the first domestically produced PD-L1 will be approved soon!
Time of Update: 2021-11-14
》The price of cabbage reappeared in China Times' "Magical Tumor Drug": Yuheng Bio-PD-1 is 3,300 yuan a piece, or the new round of medical insurance negotiations will reduce the annual cost to 30,000-40,000 yuan?
-
Junshi Biotechnology completed the world's first anti-PD-1/TGF-β bifunctional fusion protein JS201 clinical trial for the first patient administration
Time of Update: 2021-08-04
Therefore, targeting PD-1 and TGF-β at the same time is expected to improve the immunosuppressive state of the tumor microenvironment, relieve the tumor progression caused by TGF-β , and enhance the anti-tumor activity of immune drugs, thereby allowing patients to obtain better curative effects .
-
The world's first first-line treatment of esophageal cancer PD-1 was born!
Time of Update: 2021-04-21
The results of the interim analysis of KEYNOTE-590 showed that in the first-line treatment of patients with locally advanced and metastatic esophageal cancer, pembrolizumab combined with chemotherapy compared with conventional chemotherapy has brought benefits to the entire population, significantly improved overall survival, and reduced The risk of death from disease is 27%, and the safety is controllable.
-
The world's first first-line treatment of esophageal cancer PD-1 was born!
Time of Update: 2021-03-26
The results of the interim analysis of KEYNOTE-590 showed that in the first-line treatment of patients with locally advanced and metastatic esophageal cancer, pembrolizumab combined with chemotherapy compared with conventional chemotherapy has brought benefits to the entire population, significantly improved overall survival, and reduced The risk of death from disease is 27%, and the safety is controllable.
-
The world's first off-skin injection of PD-L1 antibodies! Corning Jerry KN035 (Nwolly single anti
Time of Update: 2021-01-26
January 19, 2021 // -- Corning Jerry Biopharmaceuticals ("Corning Jerry") recently announced that its recombinant humanized PD-L1 mono-domain antibody Nvolly monoantigen injection (research and develo
-
PD-1 health care negotiations dust settled: the price results are secretive and capacity is better than the rest of the world
Time of Update: 2021-01-03
PD-1 manufacturers have disclosed the annual output of antibody raw liquid production capacity according to the latest information of Junshi Bio to the IPO prospectine submitted to the board, the company has two production bases.
-
The world's first underskin injection of PD-L1 antibodies has been completed in a U.S.-registered clinical trial
Time of Update: 2020-12-24
KN035 (Nwolly monoantigen injection) has been in China, the United States and Japan for a number of tumor adaptations simultaneous clinical trials, multiple adaptations have entered the registered / III.
-
The world's first off-the-skin injection of PD-L1 antibody Nwolly monoantigen injection was submitted to China for the new drug market application
Time of Update: 2020-11-29
(3D Pharmaceuticals Inc.) has reached a strategic partnership to restructure the humanized PD-L1 mono-domain antibody Nvolly monoantigen injection (research and development code: KN035) of the new drug market application (NDA), has been officially Submitted to the National Drug Administration (NMPA), the application for adaptation is for the treatment of advanced colorectal cancer (MSI-H) advanced colorectal cancer, stomach cancer and other mismatch repair functional defects (dMMR) advanced solid tumors that have failed in previous standard treatments.